In vitro bactericidal activity of iclaprim in human plasma

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4542-4544

  Laue, Heike ^a,b   Valensise, Tiziana ^a,c   Seguin, Auréguin ^a,c   Lociuro, Sergio ^a   Islam, Khalid ^a   Hawser, Stephen ^a,d  

^a Arpida Ltd   (Switzerland)

^b GIVAUDAN SCHWEIZ AG   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDIC ACID; ICLAPRIM; LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DRUG ACTIVITY; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PLASMA; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PLASMA; PYRIMIDINES; STAPHYLOCOCCUS AUREUS;

EID: 70349345798     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00766-09     Document Type: Article

References (12)

1. Bailey, E. M., M. J. Rybak, and G. W. Kaatz. 1991. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob. Agents Chemother. 35:1089-1092.
2. Bryskier, A. (ed.). 2005. Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington, DC.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard, 7th ed. CLSI document M7-A7, vol.26, no.2. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Collignon, P., and J. Turnidge. 1999. Fusidic acid in vitro activity. Int. J. Antimicrob. Agents 12(Suppl. 2):S45-S58.
5. Dykhuizen, R. S., G. Harvey, N. Stephenson, D. Nathwani, and I. M. Gould. 1995. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob. Agents Chemother. 39:1842-1847.
6. Eliopoulos, G. M., and R. C. Moellering, Jr. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Lippincott Williams and Wilkins, Baltimore, MD.
7. Laue, H., T. Valensise, A. Seguin, S. Hawser, S. Lociuro, and K. Islam. 2007. Effect of human plasma on the antimicrobial activity of iclaprim in vitro. J. Antimicrob. Chemother. 60:1388-1390.
8. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343.
9. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents, approved guideline, NCCLS document M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
10. Oefner, C., M. Bandera, A. Haldimann, H. Laue, H. Schulz, S. Mukhija, S. Parisi, L. Weiss, S. Lociuro, and G. E. Dale. 2009. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J. Antimicrob. Chemother. 63:687-698.
11. Peppard, W. J., and C. D. Schuenke. 2008. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr. Opin. Investig. Drugs 9:210-225.
12. Rybak, M. J., D. M. Cappelletty, T. Moldovan, J. R. Aeschlimann, and G. W. Kaatz. 1998. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU- 100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents Chemother. 42:721-724.